The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.

While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

COVIC-19 clinical trial - 07/04/2022

Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity

Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.

In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.

Macrophages interacting with cytomegaloviruses - 22/02/2022

Cytomegaloviruses subvert macrophage identity

Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.

The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.

Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.

Drugs consist of molecules developed in the drug laboratory that bind to their target, usually a protein, and thus exert their effect. The actual duration of binding of a drug molecule to its target protein varies depending on the drug. The lifetime of the drug-target complex can play a critical role in the efficacy of a drug, as a long residence time at the target can be crucial for the drug's action in some cases.

The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.

Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.

Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.

A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.

The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.

At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.